I2Cure Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-06-2024
- Paid Up Capital ₹ 0.10 M
as on 16-06-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 4.05 Cr
as on 16-06-2024
- Revenue 270.58%
(FY 2022)
- Profit 137.72%
(FY 2022)
- Ebitda 134.18%
(FY 2022)
- Net Worth 38.36%
(FY 2022)
- Total Assets 285.32%
(FY 2022)
About I2Cure
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.05 Cr.
Somenath Ghosh and Anil Kejriwal serve as directors at the Company.
- CIN/LLPIN
U24290DL2020PTC365048
- Company No.
365048
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does I2cure Private Limited offer?
I2Cure Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Common Disease Medicines, Oral Care Products.
Who are the key members and board of directors at I2Cure?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Somenath Ghosh  | Additional Director | 15-Feb-2024 | Current |
Anil Kejriwal  | Director | 19-Jun-2020 | Current |
Financial Performance of I2Cure.
I2Cure Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 270.58% increase. The company also saw a substantial improvement in profitability, with a 137.72% increase in profit. The company's net worth Soared by an impressive increase of 38.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I2Cure?
In 2022, I2Cure had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 May 2022 | ₹4.00 Cr | Open |
Others Creation Date: 20 Jun 2021 | ₹0.50 M | Open |
How Many Employees Work at I2Cure?
I2Cure has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I2Cure, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I2Cure's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
